Search

Your search keyword '"Piña-Fuentes, Dan A. I."' showing total 2 results
Start Over Author "Piña-Fuentes, Dan A. I." Topic sars-cov-2
2 results on '"Piña-Fuentes, Dan A. I."'

1. [Clinical course of COVID-19 in the Netherlands: an overview of 2607 patients in hospital during the first wave].

Author

Ariës MJH, van den Bergh JP, Beudel M, Boersma W, Dormans T, Douma RA, Eerens A, Elbers PWG, Fleuren LM, Gritters van den Oever NC, de Haan L, van der Horst IJCC, Hu S, Hubers D, Janssen MLF, de Kruif M, Kubben PL, van Kuijk SMJ, Noordzij PG, Ottenhoff M, Piña-Fuentes DAI, Potters WV, Reidinga AC, Renckens RSC, Rigter S, Rusch D, Schinkel M, Sigaloff KCE, Simsek S, Stassen P, Stassen R, Thomas RM, van Wingen GA, Vonk Noordegraaf A, Welling M, Wiersinga WJ, Wolvers MDJ, and Wyers CE

Subjects
Age Factors, Aged, Comorbidity, Critical Care methods, Critical Care statistics & numerical data, Female, Hospital Mortality, Humans, Kaplan-Meier Estimate, Male, Netherlands epidemiology, Risk Factors, Severity of Illness Index, COVID-19 epidemiology, COVID-19 prevention & control, COVID-19 therapy, Cardiovascular Diseases epidemiology, Diagnostic Tests, Routine methods, Diagnostic Tests, Routine statistics & numerical data, SARS-CoV-2 isolation & purification
Abstract

Objective: To systematically collect clinical data from patients with a proven COVID-19 infection in the Netherlands., Design: Data from 2579 patients with COVID-19 admitted to 10 Dutch centers in the period February to July 2020 are described. The clinical data are based on the WHO COVID case record form (CRF) and supplemented with patient characteristics of which recently an association disease severity has been reported., Methods: Survival analyses were performed as primary statistical analysis. These Kaplan-Meier curves for time to (early) death (3 weeks) have been determined for pre-morbid patient characteristics and clinical, radiological and laboratory data at hospital admission., Results: Total in-hospital mortality after 3 weeks was 22.2% (95% CI: 20.7% - 23.9%), hospital mortality within 21 days was significantly higher for elderly patients (> 70 years; 35, 0% (95% CI: 32.4% - 37.8%) and patients who died during the 21 days and were admitted to the intensive care (36.5% (95% CI: 32.1% - 41.3%)). Apart from that, in this Dutch population we also see a risk of early death in patients with co-morbidities (such as chronic neurological, nephrological and cardiac disorders and hypertension), and in patients with more home medication and / or with increased urea and creatinine levels., Conclusion: Early death due to a COVID-19 infection in the Netherlands appears to be associated with demographic variables (e.g. age), comorbidity (e.g. cardiovascular disease) but also disease char-acteristics at admission.

Published
2021

2. Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial

Author

Lim, Endry H. T., Vlaar, Alexander P. J., Bos, Lieuwe D. J., van Vught, Lonneke A., Boer, Anita M. Tuip-de, Dujardin, Romein W. G., Habel, Maria, Xu, Zhongli, Brouwer, Matthijs C., van de Beek, Diederik, de Bruin, Sanne, van Agtmael, Michiel, Algera, Anne Geke, Appelman, Brent, van Baarle, Floor, Beudel, Martijn, Bogaard, Harm Jan, Bomers, Marije, Bonta, Peter, Botta, Michela, de Brabander, Justin, Bree, Godelieve, Bugiani, Marianna, Bulle, Esther, Chouchane, Osoul, Cloherty, Alex, Buis, David T. P., de Rotte, Maurits C. F. J., Dijkstra, Mirjam, Dongelmans, Dave A., Elbers, Paul, Fleuren, Lucas, Geerlings, Suzanne, Geijtenbeek, Theo, Girbes, Armand, Goorhuis, Bram, Grobusch, Martin P., Hagens, Laura, Hamann, Jorg, Harris, Vanessa, Hemke, Robert, Hermans, Sabine M., Heunks, Leo, Hollmann, Markus, Horn, Janneke, Hovius, Joppe W., de Jong, Menno D., Koning, Rutger, van Mourik, Niels, Nellen, Jeannine, Nossent, Esther J., Paulus, Frederique, Peters, Edgar, Piña-Fuentes, Dan A. I., van der Poll, Tom, Preckel, Bennedikt, Prins, Jan M., Raasveld, Jorinde, Reijnders, Tom, Schinkel, Michiel, Schrauwen, Femke A. P., Schultz, Marcus J., Schuurman, Alex, Schuurmans, Jaap, Sigaloff, Kim, Slim, Marleen A., Smeele, Patrick, Smit, Marry, Stijnis, Cornelis S., Stilma, Willemke, Teunissen, Charlotte, Thoral, Patrick, Tsonas, Anissa M., Tuinman, Pieter R., van der Valk, Marc, Veelo, Denise, Volleman, Carolien, de Vries, Heder, van Vugt, Michèle, Wouters, Dorien, Zwinderman, Aeilko H., Wiersinga, W. Joost, Graduate School, Intensive Care Medicine, ANS - Amsterdam Neuroscience, AII - Amsterdam institute for Infection and Immunity, ACS - Microcirculation, AII - Inflammatory diseases, ACS - Heart failure & arrhythmias, AII - Infectious diseases, ACS - Diabetes & metabolism, APH - Personalized Medicine, Neurology, ANS - Neuroinfection & -inflammation, ACS - Pulmonary hypertension & thrombosis, Center of Experimental and Molecular Medicine, ANS - Neurodegeneration, Pulmonology, ACS - Amsterdam Cardiovascular Sciences, Experimental Immunology, Infectious diseases, Laboratory for General Clinical Chemistry, Genetic Metabolic Diseases, APH - Quality of Care, APH - Aging & Later Life, APH - Global Health, Global Health, Radiology and Nuclear Medicine, AMS - Musculoskeletal Health, AMS - Sports, APH - Methodology, Anesthesiology, Medical Microbiology and Infection Prevention, Nursing, Epidemiology and Data Science, AII - Cancer immunology, APH - Digital Health, and APH - Health Behaviors & Chronic Diseases

Subjects
C5a, Complement inhibition, SARS-CoV-2, Vilobelimab, Complement, COVID-19
Abstract

We recently reported in the phase 3 PANAMO trial that selectively blocking complement 5a (C5a) with vilobelimab led to improved survival in critically ill COVID-19 patients. C5a is an important contributor to the innate immune system and can also activate the coagulation system. High C5a levels have been reported in severely ill COVID-19 patients and correlate with disease severity and mortality. Previously, we assessed the potential benefit and safety of vilobelimab in severe COVID-19 patients. In the current substudy of the phase 2 PANAMO trial, we aim to explore the effects of vilobelimab on various biomarkers of inflammation and coagulation. Between March 31 and April 24, 2020, 17 patients with severe COVID-19 pneumonia were enrolled in an exploratory, open-label, randomised phase 2 trial. Blood markers of complement, endothelial activation, epithelial barrier disruption, inflammation, neutrophil activation, neutrophil extracellular trap (NET) formation and coagulopathy were measured using enzyme-linked immunosorbent assay (ELISA) or utilizing the Luminex platform. During the first 15 days after inclusion, change in biomarker concentrations between the two groups were modelled with linear mixed-effects models with spatial splines and compared. Eight patients were randomized to vilobelimab treatment plus best supportive care (BSC) and nine patients were randomized to BSC only. A significant decrease over time was seen in the vilobelimab plus BSC group for C5a compared to the BSC only group (p < 0.001). ADAMTS13 levels decreased over time in the BSC only group compared to the vilobelimab plus BSC group (p < 0.01) and interleukin-8 (IL-8) levels were statistically more suppressed in the vilobelimab plus BSC group compared to the BSC group (p = 0.03). Our preliminary results show that C5a inhibition decreases the inflammatory response and hypercoagulability, which likely explains the beneficial effect of vilobelimab in severe COVID-19 patients. Validation of these results in a larger sample size is warranted.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results